Medha Sasané

1.6k total citations
68 papers, 1.1k citations indexed

About

Medha Sasané is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Genetics. According to data from OpenAlex, Medha Sasané has authored 68 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Pulmonary and Respiratory Medicine, 28 papers in Oncology and 16 papers in Genetics. Recurrent topics in Medha Sasané's work include Lung Cancer Treatments and Mutations (17 papers), Hemoglobinopathies and Related Disorders (16 papers) and Gastrointestinal Tumor Research and Treatment (14 papers). Medha Sasané is often cited by papers focused on Lung Cancer Treatments and Mutations (17 papers), Hemoglobinopathies and Related Disorders (16 papers) and Gastrointestinal Tumor Research and Treatment (14 papers). Medha Sasané collaborates with scholars based in United States, Canada and United Kingdom. Medha Sasané's co-authors include Carole Paley, Kenneth W. Culver, Francis Vekeman, Mei Sheng Duh, Annie Guérin, Morey A. Blinder, Roy Nitulescu, Eric Q. Wu, Anand A. Dalal and Kathleen Beusterien and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Medha Sasané

64 papers receiving 1.0k citations

Peers

Countries citing papers authored by Medha Sasané

Since Specialization

Citations

This map shows the geographic impact of Medha Sasané's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Medha Sasané with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Medha Sasané more than expected).

Fields of papers citing papers by Medha Sasané

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Medha Sasané. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Medha Sasané. The network helps show where Medha Sasané may publish in the future.

Co-authorship network of co-authors of Medha Sasané

This figure shows the co-authorship network connecting the top 25 collaborators of Medha Sasané. A scholar is included among the top collaborators of Medha Sasané based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Medha Sasané. Medha Sasané is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The burden of metastatic breast cancer on caregiver productivity and quality of life: A survey study in the United States, United Kingdom, and Germany 2024 ·Journal of Cancer Policy ·(unknown), Sukyung Chung, (unknown), (unknown), (unknown), Medha Sasané, Yingjie Zheng, Suepattra G. May	2
2	Treatment patterns of patients with HR+/HER2- metastatic breast cancer receiving CDK4/6 inhibitor-based regimens: a cohort study in the French nationwide healthcare database 2024 ·Breast Cancer Research and Treatment ·Stephanie H. Read, Nadia Quignot, (unknown), (unknown), Ying Zheng, (unknown), Medha Sasané, A.L. Vataire, (unknown), François‐Clément Bidard	4
3	Qualitative Patient Interviews to Characterize the Human Burden of Advanced Basal Cell Carcinoma Following Hedgehog Pathway Inhibitor Treatment 2023 ·Dermatology and Therapy ·(unknown), Diana Rofail, Jason A. Randall, (unknown), Chieh-I Chen, (unknown), (unknown), Medha Sasané, Tara Symonds	2
4	HTA230 Comparative Evaluation of the Performance of Two Value Attribution Frameworks When Applied to Combination Regimens in Oncology 2023 ·Value in Health ·(unknown), Harbinder Sandhu, (unknown), (unknown), Yonglan Zheng, Medha Sasané	0
5	1087P Time to clinically meaningful changes in pain in patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab in a phase II clinical trial 2020 ·Annals of Oncology ·Michael R. Migden, Danny Rischin, Stacie Hudgens, Chun‐I Chen, Chrysalyne D. Schmults, Anna C. Pavlick, Alex Guminski, Axel Hauschild, Z. Chen, Vera Mastey, (unknown), Anne Lynn S. Chang, Guilherme Rabinowits, Sherrif F. Ibrahim, Matthew G. Fury, (unknown), Medha Sasané	1
6	Real-world treatment patterns and survival of patients with BRAF V600-mutated metastatic non-small cell lung cancer 2018 ·Lung Cancer ·Leora Horn, Joshua Bauml, Patrick M. Forde, Keith L. Davis, Nathaniel J. Myall, Medha Sasané, Anand A. Dalal, (unknown), Antoinette J. Wozniak, Christina S. Baik, Alex Mutebi, Pingkuan Zhang, Heather A. Wakelee, Bruce E. Johnson	12
7	Is time to progression associated with post-progression survival in previously treated metastatic non-small cell lung cancer with BRAF V600E mutation? A secondary analysis of phase II clinical trial data 2018 ·BMJ Open ·Junlong Li, Medha Sasané, Jie Zhang, (unknown), (unknown), Zhiwen Yao, Suman Redhu, James Signorovitch	5
8	Cost Consequence Analysis Of Different Gene Mutation Testing Modalities For Braf V600E Mutation In Advanced Non-Small Cell Lung Cancer Using A Decision Analytic Model 2017 ·Value in Health ·(unknown), Zheng‐Yi Zhou, Wenxi Tang, (unknown), A. Guérin, Medha Sasané, Kui Wu, (unknown), Gregory A. Otterson, Nathan A. Pennell	1
9	Monitoring for and Characterizing Crizotinib Progression: A Chart Review of ALK-Positive Non-Small Cell Lung Cancer Patients 2017 ·Advances in Therapy ·(unknown), Anand A. Dalal, Kenneth W. Culver, (unknown), (unknown), (unknown), Medha Sasané, Alexander R. Macalalad, Annie Guérin	6
10	The economic burden of brain metastasis among lung cancer patients in the United States 2016 ·Journal of Medical Economics ·A. Guérin, Medha Sasané, (unknown), (unknown), Kenneth W. Culver, Roy Nitulescu, E.Q. Wu, Alexander R. Macalalad	37
11	Characteristics, treatment patterns, and survival among ALK+ non-small cell lung cancer (NSCLC) patients treated with crizotinib: A chart review study 2016 ·Lung Cancer ·J. Cadranel, Keunchil Park, Óscar Arrieta, Miklos Pless, (unknown), (unknown), Medha Sasané, (unknown), Elyse Swallow, (unknown), Andrew Kageleiry, Karen Stein, (unknown), Jie Zhang	18
12	ALK rearrangement testing and treatment patterns for patients with ALK-positive non-small cell lung cancer 2015 ·Cancer Epidemiology ·Annie Guérin, Medha Sasané, Jie Zhang, Alexander R. Macalalad, (unknown), (unknown), Andrew Kageleiry, Kenneth W. Culver, Eric Q. Wu, Heather A. Wakelee	13
13	High Cost Patients And Cost Patterns From Pediatric To Adult Care In A Medicaid Population With Sickle Cell Disease 2014 ·Value in Health ·Morey A. Blinder, Medha Sasané, Jonathan Fortier, Carole Paley, (unknown), Francis Vekeman	1
14	Economic Burden and Treatments of Progression to Metastatic Disease in ALK+ NSCLC Patients 2014 ·International Journal of Radiation OncologyBiologyPhysics ·A. Guérin, Medha Sasané, (unknown), Kenneth W. Culver, Alexander R. Macalalad, Roy Nitulescu, (unknown), (unknown)	1
15	Survival, healthcare resource use and costs among stage IV ER + breast cancer patients not receiving HER2 targeted therapy: a retrospective analysis of linked SEER-Medicare data 2014 ·BMC Health Services Research ·Kathleen Lang, Huan Huang, Medha Sasané, (unknown), Yanni Hao, Joseph Menzin	6
16	Age‐related treatment patterns in sickle cell disease patients and the associated sickle cell complications and healthcare costs 2013 ·Pediatric Blood & Cancer ·Morey A. Blinder, Francis Vekeman, Medha Sasané, (unknown), Carole Paley, Mei Sheng Duh	99
17	Comparison of Different Adjuvant Therapies for 9 Resectable Cancer Types 2013 ·Postgraduate Medicine ·(unknown), Anju Parthan, John Coombs, Medha Sasané, Douglas C.A. Taylor	1
18	Long-term persistency and costs associated with the use of iron chelation therapies in the treatment of Sickle cell disease within Medicaid programs 2012 ·Journal of Medical Economics ·Edward P. Armstrong, Grant H. Skrepnek, Medha Sasané, Susan Snodgrass, Samir K. Ballas	9
19	Comparison of the Long-Term Risk of Recurrence and Other Clinical Outcomes in GIST Patients Receiving Imatinib as Adjuvant Therapy—A Retrospective Chart Extract-Based Approach 2012 ·Journal of Gastrointestinal Cancer ·Anthony P. Conley, Annie Guérin, Medha Sasané, Geneviève Gauthier, (unknown), Christopher Hunt Keir, Eric Q. Wu	2
20	Economic impact on US Medicare of a new diagnosis of myelodysplastic syndromes and the incremental costs associated with blood transfusion need 2012 ·Transfusion ·Stuart L. Goldberg, Er Chen, Medha Sasané, Carole Paley, Amy Guo, Marianne Laouri	34

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact